Schedule 13D ownership disclosure
Corvus Pharmaceuticals Inc
Common stock · CUSIP: 221015100
Event date: 2025-04-29
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ORBIMED ADVISORS LLCReported CIK 0001055951
Shares: 9,785,423.00 · Class: 13.8%
- ORBIMED CAPITAL GP V LLCReported CIK 0001615374
Shares: 9,785,423.00 · Class: 13.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-25-000444
- Form type
- SCHEDULE 13D/A
- Filer
- Corvus Pharmaceuticals, Inc.
- CIK
- CIK 1626971
- Filed
- May 01, 2025
- Reporting period
- Apr 29, 2025
- Description
- Schedule 13D beneficial ownership